Bio-Rad Laboratories, Inc. (BIO.B) stock
BIO.BNYSELaboratory Analytical InstrumentsFiscal year ends December 31Also trades as BIO
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 4, 2026Score 8/3055% above fair value
$379.50+0.00 (0.00%)
Close on Oct 29, 2026Market cap $10.18BP/E 46.2Yield –
Bio-Rad Laboratories operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Bio-Rad Laboratories's operating income for the twelve months ending Jun 30, 2026 was $53.10M, down 76.3% year over year. For fiscal 2025 it was $47.20M, down 82.5% from the year before. Over ten years it grew -11.9% a year on average. The highest annual figure on record is $500.34M in fiscal 2021.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $47.20M | -82.5% |
| FY2024 | Dec 31, 2024 | $269.00M | -20.4% |
| FY2023 | Dec 31, 2023 | $337.80M | -30.0% |
| FY2022 | Dec 31, 2022 | $482.60M | -3.5% |
| FY2021 | Dec 31, 2021 | $500.34M | +18.8% |
| FY2020 | Dec 31, 2020 | $421.33M | +83.5% |
| FY2019 | Dec 31, 2019 | $229.66M | – |
| FY2018 | Dec 31, 2018 | -$103.34M | -186.7% |
| FY2017 | Dec 31, 2017 | $119.25M | +114.0% |
| FY2016 | Dec 31, 2016 | $55.72M | -66.6% |
| FY2015 | Dec 31, 2015 | $166.71M | +11.2% |
| FY2014 | Dec 31, 2014 | $149.98M | -11.5% |
| FY2013 | Dec 31, 2013 | $169.46M | -35.9% |
| FY2012 | Dec 31, 2012 | $264.18M | -13.5% |
| FY2011 | Dec 31, 2011 | $305.24M | +7.5% |
| FY2010 | Dec 31, 2010 | $284.01M | +23.0% |
| FY2009 | Dec 31, 2009 | $230.99M | +26.3% |
| FY2008 | Dec 31, 2008 | $182.94M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $72.60M | -5.8% |
| Q1 FY2026 | Mar 31, 2026 | $34.10M | +43.9% |
| Q4 FY2025 | Dec 31, 2025 | -$118.90M | -303.9% |
| Q3 FY2025 | Sep 30, 2025 | $65.30M | +1.2% |
| Q2 FY2025 | Jun 30, 2025 | $77.10M | -24.0% |
| Q1 FY2025 | Mar 31, 2025 | $23.70M | -46.9% |
| Q4 FY2024 | Dec 31, 2024 | $58.30M | -38.8% |
| Q3 FY2024 | Sep 30, 2024 | $64.50M | -29.1% |
| Q2 FY2024 | Jun 30, 2024 | $101.50M | +13.3% |
| Q1 FY2024 | Mar 31, 2024 | $44.60M | -28.0% |
| Q4 FY2023 | Dec 31, 2023 | $95.32M | -19.7% |
| Q3 FY2023 | Sep 30, 2023 | $90.95M | -3.9% |
| Q2 FY2023 | Jun 30, 2023 | $89.62M | -27.1% |
| Q1 FY2023 | Mar 31, 2023 | $61.91M | -57.7% |
| Q4 FY2022 | Dec 31, 2022 | $118.65M | +0.6% |
| Q3 FY2022 | Sep 30, 2022 | $94.65M | -39.6% |
| Q2 FY2022 | Jun 30, 2022 | $122.89M | -1.5% |
| Q1 FY2022 | Mar 31, 2022 | $146.41M | +45.2% |
| Q4 FY2021 | Dec 31, 2021 | $117.89M | -36.5% |
| Q3 FY2021 | Sep 30, 2021 | $156.80M | +43.1% |
| Q2 FY2021 | Jun 30, 2021 | $124.78M | +141.2% |
| Q1 FY2021 | Mar 31, 2021 | $100.86M | +35.6% |
| Q4 FY2020 | Dec 31, 2020 | $185.61M | +213.5% |
| Q3 FY2020 | Sep 30, 2020 | $109.60M | +90.7% |
| Q2 FY2020 | Jun 30, 2020 | $51.74M | -8.2% |
| Q1 FY2020 | Mar 31, 2020 | $74.37M | +31.4% |
| Q4 FY2019 | Dec 31, 2019 | $59.21M | – |
| Q3 FY2019 | Sep 30, 2019 | $57.46M | +58.4% |
| Q2 FY2019 | Jun 30, 2019 | $56.39M | +28.8% |
| Q1 FY2019 | Mar 31, 2019 | $56.61M | +29.7% |
| Q4 FY2018 | Dec 31, 2018 | -$227.05M | -594.7% |
| Q3 FY2018 | Sep 30, 2018 | $36.28M | -6.4% |
| Q2 FY2018 | Jun 30, 2018 | $43.79M | – |
| Q1 FY2018 | Mar 31, 2018 | $43.65M | +66.5% |
| Q4 FY2017 | Dec 31, 2017 | $45.90M | – |
| Q3 FY2017 | Sep 30, 2017 | $38.76M | +70.8% |
| Q2 FY2017 | Jun 30, 2017 | -$1.70M | – |
| Q1 FY2017 | Mar 31, 2017 | $26.21M | – |
| Q4 FY2016 | Dec 31, 2016 | -$28.20M | – |
| Q3 FY2016 | Sep 30, 2016 | $22.70M | – |